New test aims to predict cancer return after bone marrow transplant

NCT ID NCT06569095

Recruiting now Knowledge-focused Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether detecting MDS stem cells using a special lab test (flow cytometry) can predict if the disease will come back after a stem cell transplant. Researchers will follow 163 MDS patients for one year after transplant to see if this method is better than current monitoring. The goal is to improve early detection of relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a better way to predict relapse in MDS patients after transplant, helping doctors intervene earlier.
What could go wrong: This is an observational study, not a treatment trial. It may not show a clear benefit, and results may not apply to all MDS patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome myelodysplastic syndrome with excess blasts Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Chinese PLA General Hospital
RECRUITING

Beijing, China
Peking University People's Hospital
RECRUITING

Beijing, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, China
Wuhan TongJi Hospital
RECRUITING

Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.